News -

The latest issue of the journal Gen highlights iLite™ reporter gene assays

An article on the characteristics and utility of Euro Diagnostica´s cell based assays, iLite™, was published in the latest issue of the journal Gen (Nov 1, 2015 (Vol. 35, No. 19)).

The article highlights how the iLite™ reporter gene cell lines can quantify the activity of a range of biopharmaceuticals as well as antibody-dependent cytotoxicity. The iLite™ portfolio includes assays for a number of interleukins, interferons, and TNF-α, and new cell lines are in pipeline. “The main advantage for these assays is that these same cell lines can be used in drug discovery, for quantifying drug potency, and to analyze the functional drug levels and antidrug neutralizing antibodies”, says Dr. Michael Tovey, Managing Director of Biomonitor SAS, Euro Diagnostica’s newly established innovation and development centre in Paris.

Read the full article here.

You find more information about the iLite™ technology and product offerings here.

Related links

Topics

  • Medicine, Pharmaceuticals

Categories

  • ilite cell-based assays
  • knowledge

Related media

  • iLite™ Technology 3D picture
  • License: © All rights reserved (allow download)
Download

Related content

Euro Diagnostica merges with Biomonitor – enters the fields of theranostics and personalized medicine

Euro Diagnostica, a leader in diagnostic solutions for autoimmune diseases, has entered into a merger agreement with Biomonitor, a leading company in theranostics and personalized medicine. Biomonitor’s patented cell-based assay platform iLite™, based on reporter gene technology, can both monitor functional drug activity and detect neutralizing antibodies.

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

New Scientific Poster on iLite™ Insulin Assay Ready Cell line – Download it now!

Performance data and product characteristics for a new iLite™ Insulin Assay Ready Cell line responsive to insulin was presented in a scientific poster at the PEGS Boston 2016 Summit. Make sure you download it now!

Announcing the launch of iLite™ VEGF Assay Ready Cells

The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

Discover new iLite™ IL-23 Assay Ready Cells

We are happy to introduce the iLite™ IL-23 Assay Ready Cells offering significant benefits as compared to conventional IL-23 assays. Using the iLite™ IL-23 Assay Ready Cells, a rapid assay for the functional activity of IL-23, without cross-reactivity with IL-12, can easily be set-up. Results are obtained within 6 h.

Euro Diagnostica is now launching a TLR4 responsive cell line, strengthening the iLite™ Assay Ready Cell portfolio within inflammation.

Toll-like receptor 4 (TLR4) plays a fundamental role in the activation of the innate immune response, which is why drug development of TLR4 antagonists is a hot topic for treatment of inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and multiple sclerosis.